Of note, temozolomide yielded a response rate of 38% for brain metastases due to SCLC.In a clinical trial of 50 patients, combination of olaparib and temozolomide in relapsed small-cell lung cancer yielded an overall response rate of 41.7%, median progression-free survival 4.2 months, and overall survival was 8.5 months.Lurbinectedin is the most promising new agent that substantially increased overall survival rate in relapsed small cell lung cancer among sensitive disease patients. As a single agent, lurbinectedin demonstrated following clinical results in refractory small cell lung cancer trial:

Overall survival rate of 15.2 months for sensitive disease (chemotherapy-free interval of ≥ 90 days) with a disease control rate of 79.3% and overall response rate of 46.6%, and
Overall survival rate of 5.1 months for resistant (chemotherapy-free interval of < 90 days) with a disease control rate of 46.8% and overall response rate 21.3%.Lurbinectedin is also being investigated in combination with doxorubicin as second-line therapy in a randomized phase 3 trial. While overall survival in this trial is not yet known, response rates at second line were

91.7% in sensitive disease with median progression-free survival of 5.8 months , and
33.3% in resistant disease with median progression-free of 3.5 months.Lurbinectedin is currently available in the U.S. under an expanded access program (EAP).Trilaciclib, a CKD4/6 inhibitor, reduces chemotheraphy-induced toxicity in patients being treated for small-cell lung cancer. Trilaciclib’s developer, G1 Therapeutics, makes the drug available in the U.S. under expanded access while the FDA considers its New Drug Application (NDA). An approval decision on the NDA is expected by February 15, 2021.
5-year survival rates
The SEER database tracks 5-year relative survival rates based on age, sex, and race and is considered the most accurate source of survival information. This database uses terms "Localized," "Regional," and "Distant" to describe various stages of small cell lung cancer. 5-year relative survival rate for "both sexes" and "all races" affected by

"Localized" small cell lung cancer is 28.5%;
"Regional" small cell lung cancer 14.9%; and for
"Distant" small cell lung cancer 2.9%. Survival rates by sex
Women affected by small-cell lung cancer have higher 5-year survival rates than men. Localized: Women – 32.2% | Men – 24.5%
Regional: Women – 17.0% | Men – 12.3%
Distant: Women – 3.6% | Men – 2.2%

Survival rates by race, sex, age
5-year relative survival statistics are more accurate and, in some cases, higher when specific race and age range are combined with sex and stage at diagnosis. For example,

Black / Female | Ages < 50 (at diagnosis) | Distant (ES SCLC) | = 7.0%. White / Female | Ages < 50 (at diagnosis) | Distant (ES SCLC) | = 6.1%National Cancer Institutes SEER maintains publicly accessible database for specific survival rates. Epidemiology
15% of lung cancers in the US are of this type. Small cell lung cancer occurs almost exclusively in smokers – most commonly in heavy smokers and rarely in non-smokers. Recalcitrant Cancer Research Act
In 2013, the US Congress passed the Recalcitrant Cancer Research Act, which mandated increased attention to certain recalcitrant cancers, including small cell lung cancer. That led to the National Cancer Institute supporting small cell–specific research through a consortium.